Soleno Therapeutics (NASDAQ:SLNO) Posts Earnings Results, Misses Expectations By $0.13 EPS

Soleno Therapeutics (NASDAQ:SLNO) released its quarterly earnings data on Wednesday. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.13), Bloomberg Earnings reports.

NASDAQ SLNO traded up $0.07 on Friday, reaching $2.00. The company had a trading volume of 69,731 shares, compared to its average volume of 68,924. The company has a 50 day moving average of $2.56. The company has a market capitalization of $63.24 million, a PE ratio of -3.08 and a beta of 2.29. Soleno Therapeutics has a 52 week low of $1.11 and a 52 week high of $5.07.

A number of equities research analysts recently commented on SLNO shares. Zacks Investment Research downgraded Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Laidlaw started coverage on Soleno Therapeutics in a report on Monday, July 8th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine downgraded Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, June 24th.

In other Soleno Therapeutics news, major shareholder Bioasia Mangement Llc sold 90,724 shares of the stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $1.93, for a total value of $175,097.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Larry N. Feinberg purchased 57,069 shares of the stock in a transaction on Friday, July 26th. The stock was acquired at an average price of $2.14 per share, with a total value of $122,127.66. The disclosure for this purchase can be found here. Corporate insiders own 26.56% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017.

Further Reading: How does a reverse stock split work?

Earnings History for Soleno Therapeutics (NASDAQ:SLNO)

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with's FREE daily email newsletter.